Evolving target: A 16-year progressive framework for shifting the rubric of scientific publishing toward transparency, artificial intelligence, and the Economic Impact Factor for impact that matters

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 12

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Stem Cells

ISSN

1948-0210

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Stem Cells. Dec 26, 2025; 17(12): 111748
Published online Dec 26, 2025. doi: 10.4252/wjsc.v17.i12.111748

Table 7 Quantitative inputs

Parameter	Source/proxy	Normalization
Policy/regulatory citations	12 citations in FDA/EMA guidelines referencing BoNT-A complex characterization	0.8
Patent citations	27 USPTO patents citing or building on Hall A gene sequence	0.9
Start-up/corporate utilization	1 major corporate line (allergan → AbbVie post-2020)	1.0
Revenue attribution	$2.3 B annual revenue; 20 years post-publication ≥ $46 B cumulative	1.0
Healthcare cost-savings proxy	Reduction in migraine-related ER visits ≈ $0.5 B annual savings (United States estimate)	0.6

FDA: Food and Drug Administration; EMA: European Medicines Agency; USPTO: United States Patent and Trademark Office.

Citation: Li SC. Evolving target: A 16-year progressive framework for shifting the rubric of scientific publishing toward transparency, artificial intelligence, and the Economic Impact Factor for impact that matters. World J Stem Cells 2025; 17(12): 111748
URL: https://www.wjgnet.com/1948-0210/full/v17/i12/111748.htm
DOI: https://dx.doi.org/10.4252/wjsc.v17.i12.111748